These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 22204745

  • 1. Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates.
    Dowson C, Watkins J, Khan MS, Dasgupta P, Sahai A.
    Eur Urol; 2012 Apr; 61(4):834-9. PubMed ID: 22204745
    [Abstract] [Full Text] [Related]

  • 2. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, Thompson C, Zhou J, Haag-Molkenteller C.
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics.
    Kuo HC.
    Neurourol Urodyn; 2011 Sep; 30(7):1242-8. PubMed ID: 21560152
    [Abstract] [Full Text] [Related]

  • 5. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome.
    Kuo HC, Liao CH, Chung SD.
    Eur Urol; 2010 Dec; 58(6):919-26. PubMed ID: 20864251
    [Abstract] [Full Text] [Related]

  • 6. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity.
    Veeratterapillay R, Harding C, Teo L, Vasdev N, Abroaf A, Dorkin TJ, Pickard RS, Hasan T, Thorpe AC.
    Int J Urol; 2014 Feb; 21(2):175-8. PubMed ID: 23819724
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity.
    Gamé X, Khan S, Panicker JN, Kalsi V, Dalton C, Elneil S, Hamid R, Dasgupta P, Fowler CJ.
    BJU Int; 2011 Jun; 107(11):1786-92. PubMed ID: 21040367
    [Abstract] [Full Text] [Related]

  • 8. Objective and subjective improvement in children with idiopathic detrusor overactivity after intravesical botulinum toxin injection: A preliminary report.
    Al Edwan GM, Mansi HH, Atta ONM, Shaath MM, Al Adwan R, Mahafza W, Afram KM, Ababneh O, Al Adwan D, Muheilan MM.
    J Pediatr Surg; 2019 Mar; 54(3):595-599. PubMed ID: 29887168
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.
    Chen YC, Kuo HC.
    Neurourol Urodyn; 2014 Jan; 33(1):129-34. PubMed ID: 23494629
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Predictors of Poor Response and Adverse Events Following Botulinum Toxin-A for Refractory Idiopathic Overactive Bladder.
    Abrar M, Stroman L, Malde S, Solomon E, Sahai A.
    Urology; 2020 Jan; 135():32-37. PubMed ID: 31626856
    [Abstract] [Full Text] [Related]

  • 13. Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms.
    Marcelissen TA, Rahnama'i MS, Snijkers A, Schurch B, De Vries P.
    World J Urol; 2017 Feb; 35(2):307-311. PubMed ID: 27272312
    [Abstract] [Full Text] [Related]

  • 14. Botulinum toxin injections for adults with overactive bladder syndrome.
    Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D.
    Cochrane Database Syst Rev; 2011 Dec 07; (12):CD005493. PubMed ID: 22161392
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment.
    Alloussi SH, Lang Ch, Eichel R, Al-Kaabneh A, Seibold J, Schwentner C, Alloussi S.
    World J Urol; 2012 Jun 07; 30(3):367-73. PubMed ID: 21842216
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.